Schedule 13G Filing for Silexion Therapeutics Corp

This Schedule 13G filing, submitted on September 17, 2025, reports the beneficial ownership of ordinary shares in Silexion Therapeutics Corp by Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC. The filing indicates that each of the reporting persons may be deemed to beneficially own 244,771 ordinary shares, representing approximately 9.99% of the outstanding shares. The shares are subject to blocker provisions in warrants that prevent the holders from exceeding certain ownership thresholds. The filing also includes a joint filing agreement, acknowledging that the statement is filed on behalf of each of the undersigned and that subsequent amendments may be filed without additional joint filing agreements.